SRP-9001-104 en la distrofia muscular de Duchenne (DMD): Se informaron los resultados principales de tres pacientes con DMD tratados con imlifidasa antes de la administraci\u00f3n de ELEVIDYS de Sarepta en el ensayo.<\/p>\n\n\n\n
Dos ensayos de terapia g\u00e9nica, uno patrocinado por Sarepta y el otro por Genethon, respaldan la capacidad de la imlifidasa para reducir sustancialmente los anticuerpos anti-AAV y permitir la administraci\u00f3n de la terapia g\u00e9nica.<\/p>\n\n\n\n
Tras una \u00fanica dosis de imlifidasa, los pacientes experimentaron una r\u00e1pida reducci\u00f3n de los anticuerpos IgG, hasta niveles \u226595% inferiores a los basales. Adem\u00e1s, los anticuerpos anti-AAV preexistentes se redujeron por debajo de un t\u00edtulo de 1:400, lo que permiti\u00f3 el tratamiento con ELEVIDYS. No se observaron nuevas se\u00f1ales de seguridad en el ensayo. Estos primeros datos cl\u00ednicos respaldan la capacidad de la imlifidasa para reducir sustancialmente los anticuerpos anti-AAV y permitir la administraci\u00f3n de terapias g\u00e9nicas. Lea m\u00e1s sobre la imlifidasa<\/a>.<\/p>","protected":false},"excerpt":{"rendered":" SRP-9001-104 in Duchenne muscular dystrophy (DMD): Topline results were reported for three patients with DMD treated with imlifidase prior to administration of Sarepta’s ELEVIDYS in the trial. Two gene therapy trials, one sponsored by Sarepta and the other sponsored by Genethon, support the ability of imlifidase to substantially reduce anti-AAV antibodies to allow administration of […]<\/p>\n","protected":false},"author":1,"featured_media":4954,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[368,448,61,401],"class_list":["post-4953","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-aav-based-gene-therapy","tag-anti-aav","tag-gene-therapy","tag-hansa-biopharma"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4953"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4953\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4954"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4953"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}